These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 34392924)

  • 1. Immune PET Imaging.
    Iyalomhe O; Farwell MD
    Radiol Clin North Am; 2021 Sep; 59(5):875-886. PubMed ID: 34392924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
    Iravani A; Hicks RJ
    J Nucl Med; 2020 Nov; 61(11):1553-1559. PubMed ID: 32887755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
    Gao Y; Wu C; Chen X; Ma L; Zhang X; Chen J; Liao X; Liu M
    Front Immunol; 2022; 13():1049043. PubMed ID: 36341331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/Computed Tomography Transformation of Oncology: Immunotherapy Assessment.
    Ghodsi A; Hicks RJ; Iravani A
    PET Clin; 2024 Apr; 19(2):291-306. PubMed ID: 38199917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interpretation of 2-[
    Manson G; Lemchukwu AC; Mokrane FZ; Lopci E; Aide N; Vercellino L; Houot R; Dercle L
    Eur Radiol; 2022 Sep; 32(9):6536-6544. PubMed ID: 35344061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
    Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
    Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
    Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
    [No Abstract]   [Full Text] [Related]  

  • 9. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
    Aide N; Hicks RJ; Le Tourneau C; Lheureux S; Fanti S; Lopci E
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):238-250. PubMed ID: 30291373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT and the Response to Immunotherapy in Lung Cancer.
    Evangelista L; Sepulcri M; Pasello G
    Curr Radiopharm; 2020; 13(3):177-184. PubMed ID: 31858908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
    Liberini V; Laudicella R; Capozza M; Huellner MW; Burger IA; Baldari S; Terreno E; Deandreis D
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and future role of FDG-PET/CT imaging in the management of breast cancer.
    Kitajima K; Miyoshi Y
    Jpn J Radiol; 2016 Mar; 34(3):167-80. PubMed ID: 26733340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
    Cho SY; Huff DT; Jeraj R; Albertini MR
    Semin Nucl Med; 2020 Nov; 50(6):518-531. PubMed ID: 33059821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
    Castello A; Lopci E
    Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
    Shah H; Wang Y; Cheng SC; Gunasti L; Chen YH; Lako A; Guenette J; Rodig S; Jo VY; Uppaluri R; Haddad R; Schoenfeld JD; Jacene HA
    JAMA Otolaryngol Head Neck Surg; 2022 Mar; 148(3):268-276. PubMed ID: 35050348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.
    Léger MA; Routy B; Juneau D
    Semin Nucl Med; 2022 Nov; 52(6):707-719. PubMed ID: 35636978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT metabolic patterns in systemic immune activation: A new perspective on the assessment of immunotherapy response and efficacy.
    Jin P; Li J; Meng Y; Wu L; Bai M; Yu J; Meng X
    Cancer Lett; 2021 Nov; 520():91-99. PubMed ID: 34237407
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Cherk MH; Nadebaum DP; Barber TW; Beech P; Haydon A; Yap KS
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):483-494. PubMed ID: 35191204
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive value and accuracy of [
    Ayati N; Jamshidi-Araghi Z; Hoellwerth M; Schweighofer-Zwink G; Hitzl W; Koelblinger P; Pirich C; Beheshti M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2715-2726. PubMed ID: 37140669
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Prigent K; Aide N
    PET Clin; 2020 Jan; 15(1):1-10. PubMed ID: 31735296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.